Literature DB >> 35585257

The role of IFNL4 in liver inflammation and progression of fibrosis.

Michelle Møhlenberg1, Thomas R O'Brien2, Rune Hartmann3.   

Abstract

The discovery that genetic variation within the interferon lambda locus has a profound effect on the outcome of hepatitis C virus (HCV) treatment and spontaneous clearance of HCV is one of the great triumphs of genomic medicine. Subsequently, the IFNL4 gene was discovered and proposed as the causal gene underlying this association. However, there has been a lively debate within the field concerning the causality, which has been further complicated by a change in naming. This review summarizes the genetic data available for the IFNL3/IFNl4 loci and provides an in-depth discussion of causality. We also discuss a new series of interesting data suggesting that the genetic variation at the IFNL4 loci influences the evolution of the HCV virus and the implication this relationship between our genetic makeup and virus evolution has upon our understanding of the IFNL4 system. Finally, new data support an influence of the IFNL4 gene upon liver inflammation and fibrosis that is independent of etiology, thereby linking the IFNL4 gene to some of the major liver diseases of today.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35585257     DOI： 10.1038/s41435-022-00173-9

Source DB:  PubMed          Journal:  Genes Immun        ISSN： 1466-4879            Impact factor:   2.676


  56 in total

1.  [Immunity and interference in vaccinia; inhibition of skin infection by inactivated virus].

Authors:  Y NAGANO; Y KOJIMA; Y SAWAI
Journal:  C R Seances Soc Biol Fil       Date:  1954-04

Review 2.  The molecular basis for differential type I interferon signaling.

Authors:  Gideon Schreiber
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

Review 3.  IFNL4: Notable variants and associated phenotypes.

Authors:  Michelle Z Fang; Sarah S Jackson; Thomas R O'Brien
Journal:  Gene       Date:  2019-12-14       Impact factor: 3.688

4.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Authors:  Ludmila Prokunina-Olsson; Brian Muchmore; Wei Tang; Ruth M Pfeiffer; Heiyoung Park; Harold Dickensheets; Dianna Hergott; Patricia Porter-Gill; Adam Mumy; Indu Kohaar; Sabrina Chen; Nathan Brand; McAnthony Tarway; Luyang Liu; Faruk Sheikh; Jacquie Astemborski; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Timothy R Morgan; David L Thomas; Barbara Rehermann; Raymond P Donnelly; Thomas R O'Brien
Journal:  Nat Genet       Date:  2013-01-06       Impact factor: 38.330

5.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.

Authors:  Andri Rauch; Zoltán Kutalik; Patrick Descombes; Tao Cai; Julia Di Iulio; Tobias Mueller; Murielle Bochud; Manuel Battegay; Enos Bernasconi; Jan Borovicka; Sara Colombo; Andreas Cerny; Jean-François Dufour; Hansjakob Furrer; Huldrych F Günthard; Markus Heim; Bernard Hirschel; Raffaele Malinverni; Darius Moradpour; Beat Müllhaupt; Andrea Witteck; Jacques S Beckmann; Thomas Berg; Sven Bergmann; Francesco Negro; Amalio Telenti; Pierre-Yves Bochud
Journal:  Gastroenterology       Date:  2010-01-11       Impact factor: 22.682

6.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

7.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

Review 9.  Guarding the frontiers: the biology of type III interferons.

Authors:  Andreas Wack; Ewa Terczyńska-Dyla; Rune Hartmann
Journal:  Nat Immunol       Date:  2015-08       Impact factor: 25.606

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.